Vera Therapeutics Inc (NASDAQ:VERA) — Market Cap & Net Worth
Market Cap & Net Worth: Vera Therapeutics Inc (VERA)
Vera Therapeutics Inc (NASDAQ:VERA) has a market capitalization of $2.28 Billion ($2.28 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5727 globally and #1869 in its home market, demonstrating a -9.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vera Therapeutics Inc's stock price $31.77 by its total outstanding shares 71782904 (71.78 Million). Also see Vera Therapeutics Inc assets under control for a full breakdown of the balance sheet.
Vera Therapeutics Inc Market Cap History: 2021 to 2026
Vera Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows growth from $1.92 Billion to $2.28 Billion (20.94% CAGR). Also see VERA cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Vera Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.09% | #156 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.01% | #652 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.12% | #96 of 263 |
Weight: Vera Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vera Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vera Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Vera Therapeutics Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
592.92x
Vera Therapeutics Inc's market cap is 592.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.10 Billion | $1.86 Million | -$95.99 Million | 592.92x | N/A |
Competitor Companies of VERA by Market Capitalization
Companies near Vera Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Vera Therapeutics Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Vera Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Vera Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Vera Therapeutics Inc's market cap moved from $1.92 Billion to $ 2.28 Billion, with a yearly change of 20.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.28 Billion | -37.26% |
| 2025 | $3.64 Billion | +19.74% |
| 2024 | $3.04 Billion | +174.97% |
| 2023 | $1.10 Billion | -20.52% |
| 2022 | $1.39 Billion | -27.58% |
| 2021 | $1.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Vera Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.28 Billion USD |
| MoneyControl | $2.28 Billion USD |
| MarketWatch | $2.28 Billion USD |
| marketcap.company | $2.28 Billion USD |
| Reuters | $2.28 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more